Table 6.
Cohort | No-NAC | NAC | ||||||||
---|---|---|---|---|---|---|---|---|---|---|
Multivariable model 1 | Multivariable model 2 | Multivariable model | ||||||||
HR | 95% CI | P | HR | 95% CI | P | HR | 95% CI | P | ||
Age (per 1 year increase) | 1.01 | 0.98, 1.03 | 0.7 | |||||||
Chemotherapy after surgery (vs. no chemotherapy) | 0.52 | 0.34, 0.80 | 0.003 | 0.66 | 0.43, 1.02 | 0.059 | ||||
p-Stage III/IV (vs. I/II) | 2.03 | 1.25, 3.28 | 0.004 | 2.36 | 1.49, 3.72 | <0.001 | 1.35 | 0.75, 2.41 | 0.3 | |
Pleomorphic positive (vs. negative) | 1.98 | 1.07, 3.66 | 0.029 | 2.10 | 1.14, 3.86 | 0.017 | ||||
Vascular invasion positive (vs. negative) | 1.57 | 0.99, 2.49 | 0.058 | |||||||
CD20 high (vs. low) | 0.46 | 0.25, 0.83 | 0.010 | |||||||
gC1qR high (vs. low) | 0.54 | 0.30, 0.96 | 0.037 |
Data are number (%) or median (25 and 75 percentiles). *Combination based on significant interactions between 2 variables in no NAC cohort. NAC, neoadjuvant chemotherapy; gC1qR, globular heads of the C1q receptor. Bold values indicate significant p-value.